uniQure (QURE) AI Stock Analysis

• Market Cap: $820.68M
• Dividend Yield: N/A
• Average Volume (3M): 1.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: 6.30%
• EPS Growth: 29.17%
• Country: US
• Employees: 209
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 54,748,497
• 10 Day Avg. Volume: 1,157,004
• 30 Day Avg. Volume: 1,135,523
• PEG Ratio: -0.31
• Price to Book (P/B): 21.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.52
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 5.92
• Enterprise Value/Gross Profit: 74.49
• Enterprise Value/Ebitda: -0.91
• 1Y Price Target: $38.50
• Price Target Upside: 156.84% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 50 Neutral
• Price Target: $14.50 ▼(-3.27%Downside)

uniQure's stock score reflects significant financial challenges with persistent losses and a weakened balance sheet. However, positive regulatory developments for AMT-130 and a strong cash position provide some optimism. Valuation remains a concern due to negative earnings, while technical indicators suggest stabilization.

Positive Factors

Clinical Development

High-dose AMT-130 showed an 80% reduction of disease progression based on cUHDRS versus external control datasets.

Manufacturing Process

QURE will be able to use experience and knowledge from the Hemgenix manufacturing process to support their CMC requirements, which will expedite BLA filing.

Regulatory Approval

Reaching alignment with the FDA is seen as a very important de-risking event for QURE and further clarity on the content and timing of the BLA submission should bring investors some comfort.

Negative Factors

Leadership Changes

QURE is encouraged by the fact that the alignment with the FDA is consistent with previous communications from the company, despite some nervousness due to the appointment of Dr. Vinay Prasad as CBER Director.

Regulatory Challenges

Some investors might see the change here as a red flag, it's also very possible that QURE proposed the use of ENROLL-HD because they think it gives them the best shot.

uniQure Business Overview & Revenue Model

Company Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

How the Company Makes Money

uniQure generates revenue primarily through the development and commercialization of gene therapy products. The company earns money through collaborations and licensing agreements with pharmaceutical companies, which often involve upfront payments, milestone payments, and royalties on future sales of products developed with its technology. uniQure also aims to earn revenue from the direct sale of its gene therapy products once they achieve regulatory approval and enter the market. Partnerships with larger pharmaceutical companies can significantly impact its earnings by providing financial resources and sharing the risks associated with drug development.

uniQure Financial Statement Overview

Summary

uniQure's financial performance is concerning with significant revenue volatility, persistent losses, and a negative equity position indicating potential insolvency risks. Although there is some positive cash flow from investing activities, ongoing cash burn and financial instability highlight the need for strategic restructuring and revenue growth.

Income Statement

uniQure's income statement shows significant volatility in revenue and profitability. The company experienced a dramatic revenue decline from 2021 to 2023, with a slight recovery in 2024. Gross profit margin is low, and net profit margins are negative, indicating ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational challenges.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity in 2024, indicating potential insolvency risks. The debt-to-equity ratio is not calculable due to negative equity, but the company has managed to maintain a reasonable cash position. The equity ratio has deteriorated significantly, highlighting financial instability.

Cash Flow

Cash flow analysis shows negative free cash flow and operating cash flow, indicating cash burn issues. The free cash flow to net income ratio is negative, which is concerning. However, the company has managed to generate positive cash flow from investing activities in 2024, providing some liquidity relief.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.12M	15.84M	106.48M	524.00M	37.51M
Gross Profit	8.79M	2.21M	103.14M	499.03M	-84.89M
EBITDA	-160.75M	-253.10M	-108.02M	319.00M	-126.97M
Net Income	-239.56M	-308.48M	-126.79M	329.59M	-125.02M
Balance Sheet
Total Assets	556.54M	831.69M	704.96M	809.18M	340.39M
Cash, Cash Equivalents and Short-Term Investments	367.52M	617.89M	352.84M	556.26M	244.93M
Total Debt	66.06M	138.41M	142.89M	135.72M	71.54M
Total Liabilities	563.29M	624.02M	228.96M	213.40M	96.49M
Stockholders Equity	-6.75M	207.67M	476.01M	595.78M	243.91M
Cash Flow
Free Cash Flow	-186.10M	-153.08M	-162.75M	270.52M	-144.31M
Operating Cash Flow	-182.73M	-145.93M	-145.06M	287.96M	-134.83M
Investing Cash Flow	162.97M	-205.69M	-182.73M	-67.39M	-9.48M
Financing Cash Flow	-59.49M	362.72M	1.45M	94.86M	7.44M

uniQure Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QURE, the sentiment is Positive. The current price of 14.99 is above the 20-day moving average (MA) of 14.37, above the 50-day MA of 14.56, and above the 200-day MA of 12.11, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 54.28 is Neutral, neither overbought nor oversold. The STOCH value of 63.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QURE.

uniQure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	76 Outperform	$1.21B	5.94	34.46%	―	799.36%	―
NTLA	60 Neutral	$1.25B	―	-57.92%	―	-13.37%	2.57%
Sector *	52 Neutral	$7.35B	-0.07	-63.71%	2.36%	16.17%	0.03%
QURE	50 Neutral	$820.68M	―	-241.16%	―	6.30%	29.17%
DAWN	50 Neutral	$648.72M	―	-17.80%	―	―	56.10%
SYRE	43 Neutral	$983.16M	2.31	-50.47%	―	-100.00%	94.68%
RCKT	40 Underperform	$327.52M	―	-60.45%	―	―	6.99%

uniQure Corporate Events

uniQure Shareholders Approve Key Proposals at Annual Meeting

On June 11, 2025, uniQure held its Annual Meeting where shareholders voted on several key proposals. The meeting resulted in the re-election of Matthew Kapusta as executive director and Dr. Robert Gut and Dr. Jeremy Springhorn as non-executive directors, each to serve until the 2028 annual general meeting. Additionally, all other proposals, including the adoption of the 2024 Dutch statutory annual accounts, discharge of board members’ liabilities, and various authorizations related to shares and compensation, were approved.

The most recent analyst rating on (QURE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.

uniQure Aligns with FDA for AMT-130 BLA Approval

On June 2, 2025, uniQure announced alignment with the FDA on key components necessary for a Biologics License Application (BLA) for AMT-130, a gene therapy for Huntington’s disease. This alignment supports an accelerated approval pathway, with a BLA submission planned for early 2026. The company is leveraging extensive clinical data and FDA guidance to pursue the first disease-modifying treatment for Huntington’s disease, reflecting a significant step forward in addressing this unmet medical need.

The most recent analyst rating on (QURE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.